GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
Cells · 28.12.2023 · 13 (1) · 65
DOI: 10.3390/cells13010065 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 28.12.2023. Verfasst von Sydney S Wilbon und 1 weiteren Autor:innen. Beteiligte Einrichtung: The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 101-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Bovay Foundation, Levy-Longenbaugh Fund.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Glucagon-like peptide-1 receptor agonists (GLP1RA) have been transformative for patients and clinicians in treating type-2 diabetes and obesity. Drugs of this class, the bioavailability of which is continuously improving, enable weight loss and control blood glucose with minimal unwanted side effects. Since adopting GLP1RA for treating metabolic diseases, animal and clinical studies have revealed their beneficial effects on several other pathologies, including cardiovascular diseases, neurodegeneration, kidney disease, and cancer. A notable commonality between these diseases is their association with older age. Clinical trials and preclinical data suggest that GLP1RA may improve outcomes in these aging-related diseases. Some of the benefits of GLP1RA may be indirect due to their effects on obesity and glucose metabolism. However, there is building evidence that GLP1RA may also act directly on multiple organs implicated in aging-related pathology. This review aims to compile the studies reporting the effects of GLP1RA on aging-related diseases and discuss potential underlying mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, Houston, TX 77030, USA.
ORCID-Profile: Mikhail G Kolonin
Förderung
- NIDDK NIH HHS
- Bovay Foundation
- Levy-Longenbaugh Fund
- National Institute of Health
Zitieren
APA
Wilbon, S. S., & Kolonin, M. G. (2023). GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes. Cells, 13(1), 65. https://doi.org/10.3390/cells13010065
Vancouver
Wilbon SS, Kolonin MG. GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes. Cells. 2023;13(1):65. doi:10.3390/cells13010065
BibTeX
@article{Wilbon2023,
author = {Wilbon, Sydney S and Kolonin, Mikhail G},
title = {GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes},
journal = {Cells},
year = {2023},
volume = {13},
number = {1},
pages = {65},
doi = {10.3390/cells13010065}
}
EUVIMED